Viral vector bioprocessing

CELL AND GENE THERAPY INSIGHTS

April 2021

Viral vector bioprocessing

Expert Insight

Gammaretroviral and lentiviral vector manufacture: brief overview

Gammaretroviral and lentiviral vector manufacture: brief overview

Ranjita Sengupta

Innovator Insight

Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

Henrik Ihre, PhD, Peter Guterstam, MD, Mats Lundgren, PhD

Facilitating gene therapy development with solutions to four capsid analytical challenges

Facilitating gene therapy development with solutions to four capsid analytical challenges

Commentary

Making the move from antibody therapeutics to gene therapy: applicability of monoclonal antibody learnings to adeno-associated virus vector bioprocessing

Making the move from antibody therapeutics to gene therapy: applicability of monoclonal antibody learnings to adeno-associated virus vector bioprocessing

Andrew D Tustian

Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

David R Knop, PhD

FastFacts

Cell and gene manufacturing: a case study approach to overcoming challenges

Cell and gene manufacturing: a case study approach to overcoming challenges

Scalable, single-use technologies for purification of lentiviral vectors

Scalable, single-use technologies for purification of lentiviral vectors

The Corning® Ascent™ Fixed Bed Reactor (FBR) System: Designed for high yield, scalable viral vector production & other applications for cell & gene therapies.

The Corning® Ascent™ Fixed Bed Reactor (FBR) System: Designed for high yield, scalable viral vector production & other applications for cell & gene therapies.

Zara Melkoumian

Efficient and scalable purification of mRNA using affinity chromatography

Efficient and scalable purification of mRNA using affinity chromatography

Simplifying AAV protein analytics with Maurice

Simplifying AAV protein analytics with Maurice

Chris Heger PhD

The EuLV system: lentiviral vector production based on stable producer cell lines

The EuLV system: lentiviral vector production based on stable producer cell lines

Infographic

Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide

Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide

Podcast

Improving AAV vector manufacture: a question of scale

Improving AAV vector manufacture: a question of scale

Silke Wissing, Juliana Coronel

Interview

Current and future perspectives on lentiviral vector bioprocess and bioanalytical tools

Current and future perspectives on lentiviral vector bioprocess and bioanalytical tools

Improving AAV vector manufacture: a question of scale

Improving AAV vector manufacture: a question of scale

S Wissing, J Coronel, J Wölfel et al.

Keys to success for in-house lentiviral vector tech transfer and manufacture

Keys to success for in-house lentiviral vector tech transfer and manufacture

Nicole Nuñez, Liam Powers

How fixed bed bioreactors are changing the game for adherent cell culture-based vector production

How fixed bed bioreactors are changing the game for adherent cell culture-based vector production

Todd Upton, Vasiliy Goral

Webinars

Scalable suspension LVV production platforms for cell and gene therapy

Scalable suspension LVV production platforms for cell and gene therapy

S Sanyal, M Haller, Y Shin

Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

M Lundgren, P Guterstam, H Ihre

Key considerations for maximizing LV and AAV production in transient transfection workflows

Key considerations for maximizing LV and AAV production in transient transfection workflows

L Kopp, B Larimore, A Dasgupta et al.